Fed. Circ. Affirms Hanmi Win In Generic Nexium Patent Suit

Law360, Los Angeles (December 19, 2013, 4:03 PM EST) -- The Federal Circuit on Thursday found that Hanmi Pharmaceutical Co. Ltd.'s generic version of AstraZeneca AB's acid reflux drug Nexium does not infringe two of AstraZeneca's patents, upholding a lower court's construction of a key term in one of the patents.

In a unanimous decision, a three-judge panel affirmed U.S. District Judge Joel A. Pisano's claim construction ruling regarding AstraZeneca's U.S. Patent Numbers 5,714,504 and 5,877,192. AstraZeneca and Hanmi had previously agreed that Hanmi's generic Nexium does not infringe the patents under Judge Pisano's construction....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.